1.	Phase I Study of Live, Genetically Modified Salmonella typhimurium (VNP20009) for the Treatment of Cancer By Intratumoral Injection Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-005, NCI-V99-1581, NCT00004216
2.	Randomized Study of Empirical Antibacterial Therapy with Oral Ciprofloxacin/Amoxicillin-Clavulanic Acid vs Intravenous Ceftriaxone/Amikacin in Febrile Granulocytopenic Patients with Solid Tumors, Lymphoma, or Chronic Leukemia (Summary Last Modified 04/1999) Phase: No phase specified Type: Supportive care Status: Closed Age: 5 and over Sponsor: Protocol IDs: EORTC-46951
3.	Prospective, Randomized Study of Single Daily Dose of Ceftriaxone/Amikacin vs Multiple Daily Dose of Ceftazidime/Amikacin as Empirical Therapy for Fever in Cancer Patients with Granulocytopenia (Summary Last Modified 07/89) Phase: No phase specified Type: Supportive care Status: Closed Age: any age Sponsor: Protocol IDs: EORTC-46882